Eupraxia Pharmaceuticals Inc
EPRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$226.66M
Close$
$1.44
77.7% downside
Current Fair Value
77.7% downsideOvervalued by 77.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $226.66 Million |
|---|---|
| Enterprise Value | $169.98 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.03 |
| Beta | 1.5 |
| Outstanding Shares | 56,712,624 |
Return
| Return on Equity | -38.60% |
|---|---|
| Return on Assets | -36.59% |
| Return on Invested Capital | -40.86% |
Valuation & Multiples
| P/E Ratio | -6.46 |
|---|---|
| PEG | -7.65 |
| Price to Sales | - |
| Price to Book Ratio | 3.24 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 55.33%▲ 20.72% |
|---|---|
| Total Invested | $157.40M▲ 51.04% |
| Investors Holding | 54▲ 19.00% |
ESG Score
No data